06.30.21
Rentschler Biopharma is in the process of expanding its 2,000-liter bioreactor production capacity at its site in Germany. Germany is second only to the U.S. in terms of the number of manufactured biopharmaceutical active ingredients approved in the EU, however the country is falling behind in a global comparison of production capacity, ranking fifth in 2021.
"For most biopharmaceuticals currently in development, this size of bioreactor offers maximum flexibility for both clinical- and commercial-scale manufacturing, making it the optimal platform for our business at Rentschler Biopharma," explained Dr. Mathias. "We focus on supporting our clients in the development of highly complex molecules, manufacturing them safely and under the highest quality standards. We thus are making a significant contribution to the availability of life-saving therapeutics."
Rentschler Biopharma produces more than 110 different therapeutic protein formats, including monoclonal and multi-specific antibodies as well as antibody derivatives, and has thorough development and production know-how in this advanced technology. According to a Biotech Report, nearly one-third of newly approved compounds in Germany were antibodies. This technology platform will continue grow, accounting for 65% of all clinical development candidates, recombinant antibodies represent the majority of biopharmaceutical substances in clinical development, according to the report.
"Looking at the compounds currently in the pipeline, the antibodies approved to date, and the experience gained during the pandemic and previously with complex global value chains, we must ensure that patients with serious diseases have optimal access to innovative therapies. This is where Germany should see its great potential, invest further, and continue to play a leading role worldwide," said Dr. Mathias, explaining the company's plan to use the new 2,000-liter bioreactor capacity to produce novel antibody therapies or other active ingredients against serious or rare diseases.
"For most biopharmaceuticals currently in development, this size of bioreactor offers maximum flexibility for both clinical- and commercial-scale manufacturing, making it the optimal platform for our business at Rentschler Biopharma," explained Dr. Mathias. "We focus on supporting our clients in the development of highly complex molecules, manufacturing them safely and under the highest quality standards. We thus are making a significant contribution to the availability of life-saving therapeutics."
Rentschler Biopharma produces more than 110 different therapeutic protein formats, including monoclonal and multi-specific antibodies as well as antibody derivatives, and has thorough development and production know-how in this advanced technology. According to a Biotech Report, nearly one-third of newly approved compounds in Germany were antibodies. This technology platform will continue grow, accounting for 65% of all clinical development candidates, recombinant antibodies represent the majority of biopharmaceutical substances in clinical development, according to the report.
"Looking at the compounds currently in the pipeline, the antibodies approved to date, and the experience gained during the pandemic and previously with complex global value chains, we must ensure that patients with serious diseases have optimal access to innovative therapies. This is where Germany should see its great potential, invest further, and continue to play a leading role worldwide," said Dr. Mathias, explaining the company's plan to use the new 2,000-liter bioreactor capacity to produce novel antibody therapies or other active ingredients against serious or rare diseases.
